Biogen Idec Inc. (Nasdaq: BIIB) stock was up 1.6% this morning following news that the company's multiple sclerosis (MS) drug Plegridy was approved by the U.S. Food and Drug Administration on Friday.
The stock is up 14% in the last month and is still showing bullish signs.
One of yesterday's (Wednesday) biggest stock gainers, Cerulean Pharma Inc. (Nasdaq: CERU), is a biotech company that posted a 30.6% gain by day's end.
This comes at a time when short sellers are adding to their positions, waiting for a downfall of biotech, and even the country's head central banker Janet Yellen has little faith in the sector. Biotech has been on a rally over the last year, a rally that a lot of traders feel has run its course.
But biotech is still strong, and here's why...
Last week, we covered a "catalyst" that could spark a share-price rally for what is already one of the best stocks to buy, three recommendations to take advantage of rising oil prices, and a way to tap into big profits in an "other" bioscience niche that is less risky but highly lucrative.
There's nothing wrong with Big Pharma stocks, but investors need to realize they're not the only game in town. We're talking about a group of pharmaceutical stocks that possess an astounding 80% of the prescription drug market.
According to Money Morning’s BioScience Investment Specialist Ernie Tremblay, this group is an extremely profitable, and simple, way to play the pharmaceutical industry.
And yet these stocks often get overlooked...
With just six months left on my 2014 bioscience "profit calendar," things are really starting to look promising for the second half of 2014. There are huge opportunities in several subsectors of the bioscience market in particular.
That said, some bioscience analysts are saying there's a bubble. And it's scaring a lot of bioscience investors out of great positions in the market.
That's why last week I shared my complete bioscience market outlook for the rest of 2014 with my paid members - to help them see the real market story.
Today I want to share with you some of my thinking, expectations, and predictions, as well as my strategy to get us tapped in to a segment of the bioscience market we haven't even touched yet.
This segment has been tremendously profitable for some of the world's biggest drug companies, and I think there are going to be some killer profits for us there, too... Full Story
IPO Calendar 2014 update: This year, 212 companies have already held IPOs, and the healthcare industry has seen more companies go public than any sector.
Through Monday, 51 healthcare companies have made initial public offerings, accounting for 24% of the total U.S. IPO market.
Healthcare stocks are once again at the forefront of the IPO calendar this week as five of this week's seven IPOs are healthcare companies.
Here's a look at each company hitting the market this week, and the story behind each deal...
At first glance, it may seem like bioscience investing is so complicated and risky that it's hardly worth your time and money to invest, at least if you don't have someone knowledgeable to guide you.
And it's true. Putting your money behind new, experimental drugs, without some guidance, is a crapshoot.
But there's an approach to making profits from this sector that doesn't rely on breakthrough discoveries, expensive drug trials, or constant cash infusions through dilutive public offerings to fuel its engine.
That's what makes the company we'll look at today such an attractive investment.
Welcome to the lucrative world of generics...
Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) tops Tuesday's hot stocks to watch list. Shares skyrocketed 50% intraday after the biotech company deemed its cystic fibrosis treatment a success.
Also landing on today's hot stocks list are a number of penny stocks, a semiconductor company, and several stocks moving up on analysts' action and M&A activity.
Each week our Money Morning experts dish out the latest profit plays - and asset-protection moves - for our Money Morning Members - all for free.
Last week, Money Morning's best stocks to buy included five biotech picks. Four of them are blazing trails in immuno-oncology. Our fifth biotech pick has already tripled in value in the last six months, and it's not done yet.
Aside from these biotech winners, we covered an ETF play on the European Central Bank's recent policy changes, the best stock in "unified computing," and a smart gold buy at a discount.
Get these plus more of our latest, best stocks to buy.
When Valeant Pharmaceuticals International Inc. (NYSE: VRX) and activist investor Bill Ackman made an unsolicited $46 billion bid to purchase Botox maker Allergan Inc. (NYSE: AGN) last week, investors got a glimpse of just how big the Botox market is globally.
And that had us pointing to our "Stocks to Buy" list...
Investors looking for stocks to buy in 2014 have had an abundance of new options as 94 companies have gone public this year, according to Renaissance Capital.
The average return for those 94 companies since their IPO date is 9%. But some stocks have far outpaced the average, and are still at great buy-in points even after huge gains.
Last week's $45.2 billion Time Warner-Comcast deal pushed the global deal tally to $336 billion so far this year - the most since 2007 - and another blockbuster deal announced this week will push that figure even higher.
On Tuesday Irish drugmaker Actavis PLC (NYSE: ACT), producer of generic and specialty urology and women's health products, agreed to buy New York-based Forest Laboratories Inc. (NYSE: FRX) for $25 billion.
To continue reading, please click here...
While gains were modest across the three major benchmarks today (Tuesday), there was nothing modest about these major gains for Furiex Pharmaceuticals (Nasdaq: FURX) stock.
Shares of Furiex more than doubled in value, surging some 150% intraday. The closed up 129.91% at $105.69. The reason: The company announced that its experimental drug eluxadoline significantly alleviated diarrhea and abdominal pain, which typically accompany irritable bowel syndrome (IBS), in two large late-stage trials.
To continue reading, please click here...
Yes, you're reading this correctly - Intercept Pharmaceuticals Inc. (Nasdaq: ICPT) stock more than tripled today (Thursday).
ICPT shares surged 300% in trading today after an analysis by an independent safety committee showed its liver disease drug met the main goal of a mid-stage trial. ICPT stock closed at $275.49, up 280.56% from Wednesday's closing price of $72.39. The stock climbed as high as $305 in intraday trading.
To continue reading, please click here...
They account for 264 million prescriptions annually in the U.S. alone, and $35 billion in annual global sales. Now doctors say these drugs could help treat an entirely different ailment, which affects hundreds of millions of people worldwide. That means sales are about to skyrocket.
And just two drug companies will reap the lion's share of the profits...
